ATA Inc.

ATA Inc. is not a good value stock. ATA Inc. is not a good growth stock. The stock will provide you with a reasonable dividend income. ATA Inc. is not very popular among insiders. ATA Inc. is a mediocre stock to choose.
Log in to see more information.
ATA, Inc. engages in the provision of computer-based testing services. It serves professional licens...

News

atai Life Sciences chief scientific officer details VLS-01 trial success - ICYMI
atai Life Sciences chief scientific officer details VLS-01 trial success - ICYMI

Proactive Investors - UK atai Life Sciences chief scientific officer details VLS-01 trial success - ICYMI...\n more…

atai Life Sciences entering catalyst-rich period with key Phase2/3 trial data ahead
atai Life Sciences entering catalyst-rich period with key Phase2/3 trial data ahead

Proactive Investors - UK atai Life Sciences entering catalyst-rich period with key Phase2/3 trial data ahead...\n more…

atai life sciences reveals positive clinical trial results and discusses FDA ruling on MDMA
atai life sciences reveals positive clinical trial results and discusses FDA ruling on MDMA

Proactive Investors - UK atai life sciences reveals positive clinical trial results and discusses FDA ruling on MDMA...\n more…

ATAI Stock Earnings: ATAI Life Sciences Misses EPS for Q2 2024
ATAI Stock Earnings: ATAI Life Sciences Misses EPS for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nATAI stock results show that ATAI Life Sciences missed analyst estimates for earnings per share the second quarter of 2024.\nThe post...\n more…

atai Life Sciences advances clinical pipeline in Q2, unveils positive VLS-01 trial results
atai Life Sciences advances clinical pipeline in Q2, unveils positive VLS-01 trial results

Proactive Investors - UK atai Life Sciences advances clinical pipeline in Q2, unveils positive VLS-01 trial results...\n more…

atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Globe Newswire Reported positive Phase 1b results of VLS-01 (buccal film DMT); expect to initiate a Phase 2 study in treatment-resistant depression patients around YE'24 Announced clinical development plans for...\n more…